Navigation Links
Ex-IITian-designed Alzheimer's Drug's Human Clinical Trials Begin

Purdue University researchers have begun the first phase of human clinical trials to test the efficacy of an Alzheimer's drug designed in-house.

The drug is based on an inhibitor developed by a team of researchers at the university. The researchers say that it may help intercept and disable the disease at an early stage.

"Millions of people suffer from this devastating disease and treatment options are very limited," said Professor Arun Ghosh, who led the creation of the treatment molecule.

"Current drugs manage the symptoms, but this could be the first disease-modifying therapy. It may be able to prevent and reverse the disease," Ghosh, who did his MSc from MSc, Indian Institute of Technology, Kanpur in 1981.

CoMentis Inc., a San Francisco-based biopharmaceutical firm co-founded by Professor Ghosh and Oklahoma Medical Research Foundation (OMRF) scientist Jordan Tang, is initiating the clinical trials of the experimental drug CTS-21166.

The trial, which comprises of 48 healthy volunteers, will measure safety, tolerability, and pharmacokinetics of CTS-21166 at various doses.

Its results are expected to be out by the end of 2007, and the researchers expect to begin phase II studies in Alzheimer's patients in 2008.

In 2000, Professor Ghosh had built an inhibitor that had the ability to bind to and inactivate the beta-secretase enzyme, which is significant to the progression of Alzheimer's. Since then he has been leading the structure-based design of these inhibitors for therapeutic intervention of the disease.

His most recent work, which led to the creation of beta-secretase inhibitor CTS-21166, was published in the Journal of Medicinal Chemistry.

"The molecule is both highly potent and highly selective, meaning it does not appear to affect other enzymes important to brain function or cause harmful side effects," Professor Ghosh said.

"It took years of work and evaluation of hundreds of molecules to achieve one with the strength and safety necessary for clinical potential," he added.


'"/>




Related medicine news :

1. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
2. Decrease in testosterone levels lead to Alzheimers
3. Smokers are prone to Alzheimers
4. Over-The-Counter Drugs May Prevent Alzheimers
5. Alzheimers followed by head injury
6. Vitamin E useful for Alzheimers
7. Staying mentally energitic prevents Alzheimers
8. Researchers trick Alzheimers Enzyme
9. Drug Offers Hope for Alzheimers disease
10. Alzheimers with psychosis runs in families
11. Blood test may aid foretell Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology: